SSA
STLN

Schonfeld Strategic Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.2K Buy
+21,234
New +$65.1K ﹤0.01% 1934
2021
Q4 		– Sell
-76,174
Closed -$757K – 2539
2021
Q3 		$757K Buy
+76,174
New +$756K 0.01% 1078

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's STLN Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 21,234 shares worth $65.2K. The stake represents ﹤0.01% of the portfolio and ranks #1934 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in STLN as recently as Q3 2021.

Schonfeld Strategic Advisors first reported a position in STLN in Q3 2021 and has held it in 2 quarters since. The position peaked at $757K in Q3 2021. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Schonfeld Strategic Advisors held 21,234 shares of Starling Oncology Institute, Inc. Common Stock worth $65.2K as of Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1934 holding.
  • Schonfeld Strategic Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2021 and has held it in 2 quarters since.
  • Schonfeld Strategic Advisors's Starling Oncology Institute, Inc. Common Stock position peaked at $757K in Q3 2021.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.